Highlight
1. Roche’s phase 3 evERA trial reported that giredestrant, a novel oral selective estrogen receptor degrader (SERD) combined with everolimus, significantly reduces disease progression or death risk by 44% in ER-positive, HER2-negative advanced breast cancer patients previously treated with CDK4/6 inhibitors and endocrine therapy.
2. The subgroup of patients harboring ESR1 mutations experienced an even more pronounced risk reduction of 62%, demonstrating enhanced efficacy in a genetically defined population.
3. The combination therapy exhibited a manageable safety profile with no new safety signals identified.
4. Although overall survival data remain immature, early trends favor the giredestrant plus everolimus combination over standard endocrine treatment plus everolimus.
